Home /
Biologic therapy – Surgery – The Netherlands Cancer Institute
|
|
| Description: |
| Patients: This Phase I/II study involved 28 patients with malignant pleural mesothelioma.
Treatment: The treatment consisted of surgery (pleuropneumonectomy) with intraoperative photodynamic therapy (the drug mTHPC). (Photodynamic therapy is a technique that uses non-thermal lasers to activate light-sensitive drugs.) Toxicity: Three patients died in the perioperative period (the period immediately preceding, during and after a surgical procedure.) One of the three deaths was directly related to photodynamic therapy. Results: The overall median survival time was 10 months. Support: The study was supported in part by Scotia Pharmaceuticals, Ltd. Scotia manufactures the drug, mTHPC. Correspondence: Paul Bass, MD, PhD |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."